Seeking Alpha
18 Nov 2026, 09:52 UTC · 3h ago
Prime Medicine, Inc. (PRME) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Impact · against what's priced in
Prime Medicine's transition toward a commercial-stage entity is accelerated by a targeted regulatory approval in 2027 for its chronic granulomatous disease program. This, combined with the first patient dose in the Wilson disease program and an active IND for the alpha-1 program, creates a dense cluster of clinical catalysts for the coming year.
- PRME+0.60
No priced-in read yet





